echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Boehringer Ingelheim's new technology for immunotherapy against cancer cell antigens

    Boehringer Ingelheim's new technology for immunotherapy against cancer cell antigens

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 21, 2021, Boehringer Ingelheim announced the acquisition of Abexxa Biologics
    .


    This acquisition will enable Boehringer Ingelheim to gain Abexxa's expertise in targeting cancer-specific proteins located inside cells and expand the range of potential cancer antigen targets


    Abexxa focuses on the development of innovative immunotherapies around the intracellular antigens presented by atypical major histocompatibility complex (MHC) class I molecules on cancer cells to directly kill tumors or mediate tumor death through immune regulation
    .


    Atypical MHC class I molecular complexes have been shown to play an important role in regulating innate and adaptive immune responses


    Abexxa's platform can generate highly specific human antibodies against these targets
    .


    The company has developed specific expertise for the atypical MHC class I molecule HLA-E, which has the potential to affect a wider range of cancer antigens


    ▲The mechanism of action of antibodies similar to TCR (picture source: reference [2])

    Reference materials:

    [1] Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches.


    [2] UTA's AbeXXa Biologics named one of 40 "Best University Startups 2017" by National Council of Entrepreneurial Tech Transfer.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.